Loading…
Immuron Limited is projected to rise to $1.53 by 2027, a +25% move from its current price of $1.23. IMRN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.18 | $1.23 | $1.28 | +0.15% |
| Jul 14 | $1.16 | $1.23 | $1.31 | +0.30% |
| Jul 15 | $1.15 | $1.24 | $1.33 | +0.45% |
| Jul 16 | $1.14 | $1.24 | $1.35 | +0.61% |
| Jul 17 | $1.13 | $1.24 | $1.36 | +0.76% |
| Jul 18 | $1.12 | $1.24 | $1.38 | +0.91% |
| Jul 19 | $1.11 | $1.24 | $1.39 | +1.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.11 | $1.24 | $1.39 | +1.06% |
| Week 2 | $1.07 | $1.26 | $1.47 | +2.14% |
| Week 3 | $1.05 | $1.27 | $1.54 | +3.23% |
| Week 4 | $1.03 | $1.28 | $1.60 | +4.33% |
| Week 5 | $1.01 | $1.30 | $1.66 | +5.44% |
| Week 6 | $0.9981 | $1.31 | $1.72 | +6.56% |
| Week 7 | $0.987 | $1.32 | $1.78 | +7.69% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Immuron Limited is a biopharmaceutical company that engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products.
The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. In additon, the company develops IMM-986, that is in pre-clinical stage.
Further, it offers technology platform.
The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Immuron Limited (IMRN) currently trades at $1.25 per share, with a market capitalization of $10.09M and a market rank of 5134.
The stock carries a near-term price forecast that pieces together a multi-year outlook. The forecast for 2026 shows an average price of $1.25 with an ROI of 0% and a neutral sentiment, followed by a sequence of rising averages and positive returns in later years.
Looking further out, the forecast envisions substantial upside by 2050, with an average price of $14.74 and a maximum of $32.84, implying an estimated ROI of 1079.2% in that year. These figures illustrate a long-run uptrend despite near-term uncertainty. These are estimates, not guarantees, and actual results may vary.
A major floor 43.1% below — a decisive break under it would weaken the trend.
The nearest floor, 13.8% below — buyers have tended to step in here.
The nearest ceiling, 17.9% above — a clean break opens room to run.
A major ceiling 33.1% above — clearing it would confirm fresh momentum.
Key IMRN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMRN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.24 | Sell | $1.23 | Buy |
| MA 10 | $1.16 | Buy | $1.19 | Buy |
| MA 20 | $1.15 | Buy | $1.16 | Buy |
| MA 50 | $1.08 | Buy | $1.09 | Buy |
| MA 100 | $0.9405 | Buy | $1.06 | Buy |
| MA 200 | $1.19 | Buy | $1.18 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.74 | Neutral |
| Stoch RSI (14) | 53.81 | Neutral |
| CCI (20) | 87.20 | Neutral |
| Williams %R (14) | -37.04 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 10.81 | Buy |
| Bollinger %B (20,2) | 0.78 | Neutral |
| Stochastic %K (14) | 62.96 | Neutral |
| TRIX (15) | 0.22 | Buy |
| Awesome (5,34) | 0.06 | Buy |
| Ultimate (7,14,28) | 65.83 | Neutral |
| Momentum (10) | 0.12 | Buy |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 1.32 | Sell |
| ADX (14) | 13.22 | Neutral |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is bullish.
RSI14 is 60, and the stock trades near key averages with a SMA50 of $1.06 and a SMA200 of $1.20. A defined support level sits at $1.00 and a resistance at $1.45, framing a range in the near term. The 30-day range for the price spans from $0.9455 to $1.65.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.70 | $1.23 | $1.87 | 0% | Neutral | |
| $1.16 | $1.53 | $2.18 | +25% | Bullish | |
| $1.48 | $2.05 | $3.06 | +66% | Bullish | |
| $2.00 | $2.88 | $4.48 | +134% | Bullish | |
| $1.90 | $2.83 | $4.57 | +130% | Bullish | |
| $1.88 | $2.88 | $4.79 | +135% | Bullish | |
| $2.04 | $3.23 | $5.51 | +163% | Bullish | |
| $1.95 | $3.18 | $5.56 | +159% | Bullish | |
| $2.35 | $3.93 | $7.01 | +220% | Bullish | |
| $2.90 | $4.99 | $9.08 | +306% | Bullish | |
| $3.14 | $6.12 | $12.09 | +398% | Bullish | |
| $7.76 | $17.25 | $38.29 | +13.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.70 | $1.23 | $1.50 | +0.00% |
| August 2026 | $1.12 | $1.34 | $1.66 | +9.01% |
| September 2026 | $1.17 | $1.41 | $1.78 | +5.30% |
| October 2026 | $1.12 | $1.37 | $1.76 | -2.64% |
| November 2026 | $1.12 | $1.38 | $1.78 | +0.08% |
| December 2026 | $1.15 | $1.43 | $1.87 | +3.98% |
Click any year to see its month-by-month IMRN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, IMRN could reach as high as $1.87, with a base case around $1.23 and support toward $0.70 — roughly 0% from $1.23. A consolidation phase looks the most probable path here.
Expect IMRN to range from $1.16 to $2.18 through 2027. The $1.53 average target implies a +25% move from current prices. That is up +25% on the projected 2026 average. Momentum favours further upside here.
The IMRN price prediction for 2028 points to an average of $2.05 (low $1.48, high $3.06) — a potential gain of +66% on today's $1.23. Buyers look set to stay in control over this stretch.
In 2029, IMRN is projected to trade between $2.00 and $4.48, averaging $2.88 — a potential gain of +134% from today's $1.23. That is up +40% on the projected 2028 average. Momentum favours further upside here.
Immuron Limited's 2030 outlook centres on $2.83, within a $1.90 to $4.57 range. That is -1% versus the projected 2029 average. That marks a +130% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, IMRN could reach as high as $4.79, with a base case around $2.88 and support toward $1.88 — roughly +135% from $1.23. Momentum favours further upside here.
Expect IMRN to range from $2.04 to $5.51 through 2032. The $3.23 average target implies a +163% move from current prices. That is up +12% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The IMRN price prediction for 2033 points to an average of $3.18 (low $1.95, high $5.56) — a potential gain of +159% on today's $1.23. Momentum favours further upside here.
In 2034, IMRN is projected to trade between $2.35 and $7.01, averaging $3.93 — a potential gain of +220% from today's $1.23. That is up +23% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Immuron Limited's 2035 outlook centres on $4.99, within a $2.90 to $9.08 range. That is up +27% on the projected 2034 average. That marks a +306% change versus current levels. Momentum favours further upside here.
By 2040, IMRN could reach as high as $12.09, with a base case around $6.12 and support toward $3.14 — roughly +398% from $1.23. Buyers look set to stay in control over this stretch.
Expect IMRN to range from $7.76 to $38.29 through 2050. The $17.25 average target implies a +13.0x move from current prices. That is up +182% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in IMRN today (≈ 813.00813 IMRN) could be worth
$14,025.05
+$13,025.05 (+1303%) by 2050 · US Dollar
Based on the average projected IMRN price of $17.25 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMRNwould be worth at today's price.
$1,000 invested in IMRN on Jul 10, 2025 (≈ 566.572243 IMRN) would be worth
$696.88
-$303.12 (-30.3%) today · 0.70× · US Dollar
Based on a IMRN entry price of $1.76 vs. today's $1.23.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.1 | $1,118.18 | +11.8% |
| 1 month ago | $1.17 | $1,051.28 | +5.1% |
| 3 months ago | $0.793 | $1,551.07 | +55.1% |
| 6 months ago | $0.976 | $1,260.25 | +26.0% |
| 1 year ago | $1.76 | $696.88 | -30.3% |
| All time (5.0y) ago | $4.85 | $253.61 | -74.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMRN forecast.
Our base-case forecast reaches $2.50 around 2029.
Implied market cap at $2.50: $20.18M
2028 forecast shows an average price of $1.97 with a 57.7% ROI and bullish sentiment, signaling a strengthening path ahead.
By 2030, the forecast shows an average price of $2.67 with a min of $1.79 and a max of $4.32, delivering a 113.8% ROI and a bullish outlook.
Looking further to 2040, the expectation is an average price of $5.38 with a min of $2.75 and a max of $10.66, corresponding to a 330.6% ROI and a bullish sentiment. By 2050, the average is projected at $14.74, with a min of $6.63 and a max of $32.84, implying a 1079.2% ROI and a bullish stance. While these projections illustrate substantial long-term upside, they are estimates and carry inherent uncertainty, with actual results depending on market and company-specific factors.
Tap a question to reveal the answer.
Avg $2.67; min $1.79; max $4.32; ROI 113.8%; sentiment BULLISH.
2026 forecast is neutral with avg $1.25 and ROI 0; from 2028 forward the outlook is bullish, with 2030 avg $2.67, 2040 avg $5.38, and 2050 avg $14.74 (ROI 1079.2%).
Yes. The forecast shows a max of $5.15 in 2032 and $6.31 in 2034, with higher implied tops by 2040 ($10.66) and 2050 ($32.84).
Current price is $1.25 and market capitalization is $10.09M.
30-day range low $0.9455 and high $1.65.
Immuron Limited Community Discussion
0Share your Immuron Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.